Chargement en cours...

Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias

INTRODUCTION: Bosutinib is a dual ABL1 and SRC third generation tyrosine kinase inhibitor (TKI) indicated for the treatment of patients with chronic myelogenous leukemia (CML) resistant to or intolerant of other BCR-ABL1 inhibitors. Bosutinib is active against leukemia cells expressing imatinib-resi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Expert Opin Orphan Drugs
Auteurs principaux: Varallo-Rodriguez, Cristina, Freyer, Craig W., Ontiveros, Evelena P., Griffiths, Elizabeth A., Wang, Eunice S, Wetzler, Meir
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6684277/
https://ncbi.nlm.nih.gov/pubmed/31388478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1036027
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!